journal article·2021-01-01Open access

Effect of ambient temperature on respiratory tract cells exposed to SARS-CoV-2 viral mimicking nanospheres—An experimental study

Sachin Kumar, Alexandra Paul, Sayantan Chatterjee, Sabine Pütz, Natasha Nehra, Daniel S. Wang, Arsalan Nisar, Christian M. Jennings, Sapun H. Parekh

Biointerphases· Volume 16· Issue 1

Abstract

The novel coronavirus caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has reached more than 160 countries and has been declared a pandemic. SARS-CoV-2 infects host cells by binding to the angiotensin-converting enzyme 2 (ACE-2) surface receptor via the spike (S) receptor-binding protein (RBD) on the virus envelope. Global data on a similar infectious disease spread by SARS-CoV-1 in 2002 indicated improved stability of the virus at lower temperatures facilitating its high transmission in the community during colder months (December–February). Seasonal viral transmissions are strongly modulated by temperatures, which can impact viral trafficking into host cells; however, an experimental study of temperature-dependent activity of SARS-CoV-2 is still lacking. We mimicked SARS-CoV-2 with polymer beads coated with the SARS-CoV-2 S protein to study the effect of seasonal temperatures on the binding of virus-mimicking nanospheres to lung epithelia. The presence of the S protein RBD on nanosphere surfaces led to binding by Calu-3 airway epithelial cells via the ACE-2 receptor. Calu-3 and control fibroblast cells with S-RBD-coated nanospheres were incubated at 33 and 37 °C to mimic temperature fluctuations in the host respiratory tract, and we found no temperature dependence in contrast to nonspecific binding of bovine serum ablumin-coated nanospheres. Moreover, the ambient temperature changes from 4 to 40 °C had no effect on S-RBD-ACE-2 ligand-receptor binding and minimal effect on the S-RBD protein structure (up to 40 °C), though protein denaturing occurred at 51 °C. Our results suggest that ambient temperatures from 4 to 40 °C have little effect on the SARS-CoV-2-ACE-2 interaction in agreement with the infection data currently reported.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: SARS-CoV-2 and COVID-19 Research · COVID-19 Clinical Research Studies · Inhalation and Respiratory Drug Delivery

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Biomedical Engineering, University of Texas at Austin 1 , Austin, Texas 78712

Department of Biology and Biological Engineering, Chalmers University of Technology 2 , Gothenburg 41296,

Department of Molecular Spectroscopy, Max Planck Institute for Polymer Research 3 , Mainz 55128,

Funding

Texas 4000 Seed Grant · Human Frontiers in Science Program · Barbro Osher Endowment · National Institutes of Health · Cancer Prevention and Research Institute of Texas · Swedish Research Council · Welch Foundation

References (63)

Show source-provided references
1. Johns Hopkins
2. J. Epidemiol. Commun. Health · 2005 · 59 · 18610.1136/jech.2004.020180 ↗
3. Epidemiol. Infect. · 2006 · 134 · 22310.1017/S0950268805005054 ↗
4. Adv. Virol. · 2011 · 734690
5. Intern. Med. J. · 2007 · 37 · 55010.1111/j.1445-5994.2007.01358.x ↗
6. Lancet Infect. Dis. · 2020 · 20 · e23810.1016/S1473-3099(20)30484-9 ↗
7. Biology · 2020 · 9 · 9410.3390/biology9050094 ↗
8. Sci. Total Environ. · 2020 · 729 · 13905110.1016/j.scitotenv.2020.139051 ↗
9. Appl. Environ. Microbiol. · 2020 · 86 · e01244
10. Med. Hypotheses · 2020 · 144 · 10995810.1016/j.mehy.2020.109958 ↗
11. Sci. Total Environ. · 2020 · 724 · 13820110.1016/j.scitotenv.2020.138201 ↗
12. Appl. Phys. Lett. · 2020 · 117 · 06060110.1063/5.0020782 ↗
13. Environ. Res. · 2020 · 186 · 10955310.1016/j.envres.2020.109553 ↗
14. Sci. Total Environ. · 2020 · 728 · 13889010.1016/j.scitotenv.2020.138890 ↗
16. Rev. Med. Virol. · 202010.1002/rmv.2153 ↗
17. Clin. Transl. Sci. · 2011 · 4 · 4810.1111/j.1752-8062.2010.00257.x ↗
18. Clin. Transl. Allergy · 2018 · 8 · 110.1186/s13601-017-0187-2 ↗
19. Int. J. Circumpolar Health · 2007 · 66 · 9110.3402/ijch.v66i2.18237 ↗
20. Med. Sci. Sports Exerc. · 1980 · 12 · 36510.1249/00005768-198025000-00012 ↗
21. Viruses · 2016 · 8 · 24410.3390/v8090244 ↗
22. Proc. Natl. Acad. Sci. U.S.A. · 2015 · 112 · 82710.1073/pnas.1411030112 ↗
23. Clin. Infect. Dis. · 2020 · 71 · 248210.1093/cid/ciaa681 ↗
24. Cmaj · 2020 · 192 · E56610.1503/cmaj.200920 ↗
26. Int. Immunopharmacol. · 2020 · 88 · 10692810.1016/j.intimp.2020.106928 ↗
27. J. Virol. · 2013 · 87 · 758510.1128/JVI.00757-13 ↗
28. Viruses · 2018 · 10 · 56010.3390/v10100560 ↗
29. Sci. Rep. · 2017 · 7 · 110.1038/s41598-016-0028-x ↗
30. Nature · 2020 · 586 · 51610.1038/s41586-020-2798-3 ↗
31. Nat. Nanotechnol. · 2020 · 1 · 64610.1038/s41565-020-0737-y ↗
32. Nat. Struct. Mol. Biol. · 2020 · 27 · 92510.1038/s41594-020-0479-4 ↗
33. Respir. Med. · 2020 · 168 · 10599610.1016/j.rmed.2020.105996 ↗
34. Proc. Natl. Acad. Sci. U.S.A. · 2020 · 117 · 1172710.1073/pnas.2003138117 ↗
35. Nanotheranostics · 2017 · 1 · 41510.7150/ntno.21723 ↗
36. Adv. Sci. · 2020 · 7 · 190320410.1002/advs.201903204 ↗
37. Elife · 2019 · 8 · e4376410.7554/eLife.43764 ↗
38. Proc. Natl. Acad. Sci. U.S.A. · 2018 · 115 · E904110.1073/pnas.1804292115 ↗
39. Clin. Vaccine Immunol. · 2017 · 24 · e0009010.1128/CVI.00090-17 ↗
40. J. Colloid Interface Sci. · 1995 · 176 · 24010.1006/jcis.1995.0027 ↗
41. Biotechnol. J. · 2019 · 14 · 180071410.1002/biot.201800714 ↗
42. Measuring cell fluorescence using ImageJ
43. Biomaterials · 2016 · 106 · 11110.1016/j.biomaterials.2016.08.018 ↗
44. Small · 2016 · 12 · 175810.1002/smll.201502458 ↗
45. Nature · 2003 · 426 · 45010.1038/nature02145 ↗
46. Cell · 2020 · 181 · 27110.1016/j.cell.2020.02.052 ↗
47. J. Control. Release · 2014 · 190 · 48510.1016/j.jconrel.2014.06.038 ↗
48. J. Vet. Sci. · 2006 · 7 · 32110.4142/jvs.2006.7.4.321 ↗
49. Chem. Sci. · 2020 · 11 · 581910.1039/D0SC01255F ↗
50. Nat. Commun. · 2020 · 11 · 110.1038/s41467-019-13877-w ↗
51. FEMS Microbiol. Rev. · 2015 · 39 · 15510.1093/femsre/fuu004 ↗
52. Nat. Commun. · 2020 · 11 · 110.1038/s41467-020-18319-6 ↗
53. J. Biol. Chem. · 1983 · 258 · 508910.1016/S0021-9258(18)32542-0 ↗
54. PLoS Comput. Biol. · 2017 · 13 · e100580510.1371/journal.pcbi.1005805 ↗
55. Biomed. Rep. · 2017 · 7 · 40010.3892/br.2017.982 ↗
56. Eur. Resp. J. · 2020 · 56 · 110.1183/13993003.01123-2020 ↗
57. Transboundary Emerg. Dis. · 2020 · 67 · 231310.1111/tbed.13631 ↗
58. J. Hosp. Infect. · 2020 · 106 · 22610.1016/j.jhin.2020.07.009 ↗
59. Compr. Rev. Food Sci. Food Saf. · 2010 · 9 · 310.1111/j.1541-4337.2009.00092.x ↗
60. Biophys. Rev. · 2020 · 1 · 8510.1007/s12551-020-00619-2 ↗
61. Rev. Med. Virol. · 2020 · 30 · e211510.1002/rmv.2115 ↗
62. Med. Microbiol. Immunol. · 2005 · 194 · 110.1007/s00430-004-0219-0 ↗
63. See supplementary material at https://doi.org/10.1116/6.0000743 for additional data on cell viability with S-RBD nanospheres, ACE-2 expression at different temperatures for Calu-3 and NIH-3T3 cells, temperature-dependent uptake of control and BSA-coated nanosphere, and thermal stability of the S-RBD until 60 °C.